Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriatic arthritis

XenoPort’s Psoriasis Drug Found Effective in Phase 2 Trial

Reuters Staff  |  September 15, 2015

(Reuters)—Drug developer XenoPort Inc. said on Tuesday its experimental drug was effective in treating psoriasis, sending its shares up 19% in premarket trading. The oral drug met the main goal in a phase 2 trial of patients with moderate-to-severe chronic plaque-type psoriasis, the company said. XenoPort said it expected to start late-stage trials next year…

Filed under:Drug Updates Tagged with:brodalumabplaque psoriasisPsoriasisPsoriatic Arthritissecukinumab

Self-Monitoring of RA Treatment May Lead to Fewer Office Visits

Reuters Staff  |  September 5, 2015

NEW YORK (Reuters Health)—Self-monitoring of methotrexate therapy may curb healthcare utilization in rheumatoid arthritis (RA) and psoriatic arthritis, according to a new trial. The study indicates “that this novel model of care led to significant reductions in outpatient visits to the (clinical nurse specialist) and a reduction in visits to the GP, while maintaining the…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Disease-modifying antirheumatic drugs (DMARDs)Methotrexatepatientpatient managementRheumatiod arthritis

RA Diagnosis Uses Lab Tests, Clinical Insight to Rule Out Lyme

Charles Radis, DO  |  August 18, 2015

What struck me first as I walked by the exam room where Lynn P. sat was the swelling in her fingers and wrists. The bloated hands rested unnaturally on her thighs, palms up, fingers slightly flexed. Her strawberry-blond curls were offset by a high-neck, loose-fitting, burgundy sweater. Her pale skin matched her trim slacks. She had…

Filed under:ConditionsRheumatoid Arthritis Tagged with:ClinicalDiagnosislab testLyme Diseasepatient careRheumatoid arthritisrheumatologist

Biosimilar Drugs for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2015

Etanercept Biosimilars A number of Phase 3 trials are ongoing for etanercept biosimilars.1 One evaluation identified three trials in rheumatoid arthritis (RA) patients and one in psoriasis patients. The psoriatic arthritis trial evaluated PASI as a primary endpoint and the following secondary endpoints: PASI50, PASI75, PASI90, PASI score, laboratory values, ECG, adverse events (AEs), injection…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsDrugsoutcomeRheumatoid arthritisrheumatologySafety

Rheumatologist Blends Mixology Hobby with Medical Career

Eric Butterman  |  August 17, 2015

It takes adjustment and patience. That sounds like rheumatology. But for Fred Murphy, DO, FACP, FACR, it also defines his other career—drink inventor. From a drink for the whole family to another he claims helps hangovers, creating beverages is a challenge he relishes. “It’s fun to see what I can come up with next,” he…

Filed under:Professional TopicsProfiles Tagged with:hobbyrheumatologist

Can Systemic Inflammation Influence Mood?

Simon M. Helfgott, MD  |  August 17, 2015

The Friday night press release: When a politician or any public figure needs to disclose unfavorable news, chances are they will release it sometime on a late Friday afternoon or evening, hoping that nobody is paying attention. In fact, this behavior was coined “the take out the trash day” on the television political drama, The…

Filed under:ConditionsOpinionOther Rheumatic ConditionsPractice SupportRheuminationsSpeak Out Rheum Tagged with:disorderdrug therapyMental Healthpatient carePsychosisrheumatologistSteroidsystemic inflammation

Evidence Lacking for Tests for Psoriasis Patients Using Biologic Agents

Will Boggs, MD  |  July 25, 2015

NEW YORK (Reuters Health)—Various organizations recommend dozens of screening and monitoring tests for patients with psoriasis or psoriatic arthritis who are using systemic biologic agents, despite sparse evidence to support any of them. “At a population level, these medications have proven to be very safe and the evidence does not support such extensive and frequent…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:BiologicsinfliximabPsoriasisPsoriatic Arthritis

Adverse Event Risk Data Drive Evaluation of Psoriasis Treatments

Michele B. Kaufman, PharmD, CGP, RPh  |  July 14, 2015

PSOLAR, the Psoriasis Longitudinal Assessment and Registry, is a multicenter, longitudinal, intercontinental, disease-based registry used to identify adverse events from commonly used psoriasis drugs.1 An evaluation of the risk of serious infection from systemic psoriasis treatments was recently published using data from PSOLAR. Ninety-three institutional review boards or ethics committees reported into the registry from…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic Conditions Tagged with:adverse eventsbrodalumabclinical trialsdatadrugoutcomePsoriasisrheumatologyriskSafety

Biosimilars for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  June 17, 2015

Biosimilars for etanercept and sarilumab are being examined in multiple Phase 3 trials for their effects in RA and psoriasis patients.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic ArthritisRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsPsoriatic Arthritis

HIV Infection: What Rheumatologists Need to Know

HIV Infection: What Rheumatologists Need to Know

Leonard H. Calabrese, DO, & Elizabeth Kirchner, MSN, CNP  |  June 15, 2015

It has been nearly 35 years since the original descriptions of what now is recognized as AIDS (the acquired immune deficiency syndrome), an advanced form of infection secondary to the human immunodeficiency virus (HIV). The epidemic of HIV infection remains the singular most dramatic epidemic of our generation and will likely remain with us for…

Filed under:ConditionsPractice Support Tagged with:AIDSHIVInfectionpatient careRheumatoid arthritisrheumatologist

  • « Previous Page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • …
  • 63
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences